Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
Phase 2
- Conditions
- Anal Cancer
- Interventions
- Registration Number
- NCT03381352
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Brief Summary
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- CT/MRI diagnosed stage cT1-4N0-3;
- Histologically confirmed anal squamous carcinoma;
- KPS >= 70
- Adequate organ function;
- No previous radiotherapy or chemotherapy;
- No surgery.
Exclusion Criteria
- Previous malignant cancer history;
- Allegic to 5-fu or MMC
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Chemo-radiotherapy with IMRT technique Chemo-radiotherapy with IMRT technique Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy Chemo-radiotherapy with IMRT technique Mitomycin C Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy Chemo-radiotherapy with IMRT technique Capecitabine Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
- Primary Outcome Measures
Name Time Method Response rate 8 weeks after IMRT To evaluate response rate of IMRT with chemotherapy
- Secondary Outcome Measures
Name Time Method Adverse events from start of IMRT to 8 weeks after IMRT To assess the adverse events of IMRT with chemotherapy
Trial Locations
- Locations (1)
Chinese academy of medical sciences
🇨🇳Beijing, Beijing, China